BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $695,493 | -7.7% | 17,990 | -9.9% | 0.02% | -9.5% |
| Q3 2023 | $753,479 | -31.2% | 19,965 | -17.0% | 0.02% | -22.2% |
| Q2 2023 | $1,095,718 | +8.9% | 24,050 | -3.1% | 0.03% | -3.6% |
| Q1 2023 | $1,006,415 | -37.5% | 24,813 | -21.5% | 0.03% | -39.1% |
| Q4 2022 | $1,610,193 | +1.8% | 31,591 | +7.6% | 0.05% | -11.5% |
| Q3 2022 | $1,582,000 | +10.6% | 29,370 | +31.9% | 0.05% | +23.8% |
| Q2 2022 | $1,430,000 | -26.3% | 22,266 | -11.0% | 0.04% | +7.7% |
| Q1 2022 | $1,940,000 | -7.8% | 25,024 | +2.1% | 0.04% | -4.9% |
| Q4 2021 | $2,103,000 | -9.4% | 24,499 | -15.2% | 0.04% | -30.5% |
| Q3 2021 | $2,322,000 | -8.5% | 28,875 | -8.4% | 0.06% | -26.2% |
| Q2 2021 | $2,537,000 | -1.1% | 31,520 | +3.7% | 0.08% | -16.7% |
| Q1 2021 | $2,564,000 | +68.0% | 30,401 | +59.9% | 0.10% | +35.2% |
| Q4 2020 | $1,526,000 | +105.4% | 19,017 | +105.9% | 0.07% | +69.0% |
| Q3 2020 | $743,000 | -67.6% | 9,238 | -65.3% | 0.04% | -88.9% |
| Q2 2020 | $2,293,000 | +2216.2% | 26,636 | +2081.5% | 0.38% | +603.7% |
| Q1 2020 | $99,000 | +57.1% | 1,221 | +61.5% | 0.05% | +315.4% |
| Q4 2019 | $63,000 | – | 756 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |